JGH Open最新文献

{"title":"Terminal Ileitis on Imaging Is Rarely Crohn's Disease: A 10-Year Retrospective Cohort Study","authors":"Irene Lu,&nbsp;Carl Cosgrave,&nbsp;Phongsakone Inthavong,&nbsp;Phillip Te,&nbsp;Zacchary Tamsett,&nbsp;Jacoba van Wees,&nbsp;Neel Heerasing","doi":"10.1002/jgh3.70459","DOIUrl":"10.1002/jgh3.70459","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Terminal ileitis is a common radiological finding in patients with abdominal pain and altered bowel habits. Although often associated with Crohn's disease (CD), it has a broad differential diagnosis including infectious, surgical, and malignant conditions. Prior studies suggest 20%–45% of terminal ileitis accounts for CD. This study aimed to evaluate the proportion of patients with computed tomography-detected (CT) terminal ileitis diagnosed with CD and to assess clinical and biochemical predictors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort study was conducted at a single tertiary hospital between 2014 and 2024. Adult patients with CT findings of terminal ileitis were included. Data were collected on demographics, laboratory values, stool testing, and endoscopic evaluation. Multivariable logistic regression was used to identify predictors of CD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 128 patients, 16 (12.5%) were diagnosed with CD. Infectious (27.7%) and surgical (17.9%) etiologies were the most common causes of non-CD terminal ileitis. Stool testing within 72 h was performed for 48.4% of patients, with 35.5% positive for pathogens. Endoscopic evaluation was performed in 59 patients (46%), and histopathological inflammation identified in 43.5% of biopsied cases. Lower albumin levels trended toward association with CD and were independently associated with CD on multivariable analysis (OR 0.82, 95% CI 0.72–0.94, <i>p</i> = 0.004).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>After evaluation, a small minority (12.5%) of patients with CT-detected terminal ileitis were diagnosed with CD. Hypoalbuminemia was a significant predictor of CD, whereas routine inflammatory markers had limited diagnostic value. Larger prospective studies are needed to further refine the diagnostic algorithms for detection of CD in patients with terminal ileitis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 8","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148714108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary Patterns and Food Choices of Adults With Inflammatory Bowel Disease in New Zealand","authors":"Peter Vivian Acire,&nbsp;Angharad Vernon-Roberts,&nbsp;Andrew S. Day","doi":"10.1002/jgh3.70457","DOIUrl":"10.1002/jgh3.70457","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to assess current dietary patterns in adults with inflammatory bowel disease (IBD) in New Zealand and to evaluate associations with current self-reported disease activity and well-being.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective online survey was conducted using validated dietary data collection instruments. Dietary patterns were derived using principal component analysis. Self-reported current disease activity and health-related quality of life (HRQoL) scores were ascertained. Relationships between diet patterns and other variables were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The responses of 205 participants were included in the analysis: mean age 43.0 (±14.0) years, and a mean disease duration of 31.5 (±14.0) years. There were 107 (52%) people with Crohn's disease (CD) and 98 (48%) with ulcerative colitis/IBD-unclassified (UC/IBDU). Six dietary patterns were identified among the cohort data: Western, vegetarian, pescatarian, semi-vegetarian, semi-pescatarian, and low-carbohydrate. Consuming a Western dietary pattern was associated with active CD (adjusted odds ratio [AOR] = 4.55, 95% CI [1.27, 7.26], <i>p</i> = 0.02) or active UC/IBDU (AOR = 3.50, 95% CI [1.07, 5.40], <i>p</i> = 0.04). In contrast, people with CD following a vegetarian diet pattern were less likely to report active disease (AOR = 0.32, 95% CI [0.11, 0.98], <i>p</i> = 0.04). Adherence to a Western or semi-pescatarian dietary pattern was predictive of worse HRQoL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this group of adults with IBD, vegetarian dietary patterns were associated with lower current CD activity but not UC/IBDU, while the Western dietary pattern was associated with higher disease activity and impaired HRQoL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 8","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13454213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148708064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Burden of Viral Respiratory Infections in Immunosuppressed Inflammatory Bowel Disease Patients","authors":"D. Huynh,&nbsp;E. Khoo,&nbsp;A. Shanmuga Anandan,&nbsp;J. Begun","doi":"10.1002/jgh3.70456","DOIUrl":"10.1002/jgh3.70456","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background and Aim&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Due to the increasing immunosuppressant use in inflammatory bowel disease (IBD) and the risk of serious infections, this study investigates the prevalence and risk factors of respiratory pathogen detection in this population to improve patient care.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A retrospective study conducted at Mater Hospital Brisbane examined viral respiratory swab results from patients with IBD who presented with respiratory symptoms between February 2020 and September 2023. Relevant clinical data—including patient characteristics, IBD treatments, and respiratory outcomes—were extracted from electronic medical records. Statistical analyses were performed using SPSS version 30, employing chi-square tests and logistic regression for univariate and multivariate analyses, with a significance threshold set at &lt;i&gt;p&lt;/i&gt; &lt; 0.05.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Total of 184 IBD patients with 288 episodes of respiratory symptoms underwent respiratory swabs and PCR. Overall detectable pathogens on respiratory swab were 14% (&lt;i&gt;n&lt;/i&gt; = 40), including 60% (&lt;i&gt;n&lt;/i&gt; = 24) COVID, 5% (&lt;i&gt;n&lt;/i&gt; = 2) RSV, 8% (&lt;i&gt;n&lt;/i&gt; = 3) Influenza and 28% (&lt;i&gt;n&lt;/i&gt; = 11) other viruses. Of the total IBD patients, the median age was 37.5 [IQR 27–55], median disease duration 7 years [IQR 3–14] and the majority diagnosed with ulcerative colitis (&lt;i&gt;n&lt;/i&gt; = 97, 52.7%) or Crohn's disease (&lt;i&gt;n&lt;/i&gt; = 80, 43.5%). The median age was 37.5 years (interquartile range [IQR] 28–55.5) in the pathogen positive detection group and 38 years (IQR 27–56.25) in the undetectable pathogen group. Most of the patients with a positive detectable respiratory pathogen had ulcerative colitis (&lt;i&gt;n&lt;/i&gt; = 22, 57.9%) or Crohn's disease (&lt;i&gt;n&lt;/i&gt; = 18, 45%). We found no significant effect of conventional or advanced IBD therapy on respiratory pathogen detection including infliximab (&lt;i&gt;p&lt;/i&gt; = 0.856), adalimumab (&lt;i&gt;p&lt;/i&gt; = 0.148), vedolizumab (&lt;i&gt;p&lt;/i&gt; = 0.957), ustekinumab (&lt;i&gt;p&lt;/i&gt; = 0.976), immunomodulator(s) (&lt;i&gt;p&lt;/i&gt; = 0.560, 0.573) or 5-ASA (&lt;i&gt;p&lt;/i&gt; = 0.758). However, concurrent prednisolone use significantly increased the risk of detectable pathogens (OR 2.78 [95% CI 1.07–7.19], &lt;i&gt;p&lt;/i&gt; = 0.035).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study found no increase in respiratory pathogen detection in IBD patients taking advanced therapies or immunomodulators, but concurrent prednisolone use was a significant risk factor. This suggests the importance of reducing steroid exposure via early introduction of steroid","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 8","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13442588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148686164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Golgi Protein 73 and Laminin-γ2 Monomer-Based Score for the Diagnosis of Advanced Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease","authors":"Xin-Tong Ng,&nbsp;Jin-Ying Teh,&nbsp;Pavai Sthaneshwar,&nbsp;Izzatul Aliaa Badaruddin,&nbsp;Pavitratha Puspanathan,&nbsp;Nik Raihan Nik Mustapha,&nbsp;Sanjiv Mahadeva,&nbsp;Wah-Kheong Chan","doi":"10.1002/jgh3.70455","DOIUrl":"10.1002/jgh3.70455","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study evaluated the diagnostic performance of Golgi protein 73 (GP73), laminin-γ2 monomer (LG2m), and the GLAS score in detecting advanced fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included patients with MASLD who underwent liver biopsy. The performance of serum levels of GP73 and LG2m and the GLAS score to diagnose advanced fibrosis was evaluated using area under receiver operating characteristic curves (AUROC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The data for 209 patients with MASLD were analyzed [median age 52 (42–58) years, 53.1% men, 71.3% had steatohepatitis, 18.1% had advanced fibrosis]. The serum levels of GP73 and LG2m and the GLAS score were significantly higher in patients with advanced fibrosis compared to patients without advanced fibrosis [GP73: 83 ± 50 ng/mL vs. 61 ± 35 ng/mL, <i>p</i> = 0.013; LG2m: 31 (14–48) pg/mL vs. 17 (12–23) pg/mL, <i>p</i> &lt; 0.001; GLAS score: 0.89 (0.49–0.97) vs. 0.47 (0.15–0.78), <i>p</i> &lt; 0.001]. The AUROC of serum levels of GP73 and LG2m and GLAS for diagnosing advanced fibrosis was 0.63 (0.52–0.74), 0.73 (0.62–0.83), and 0.72 (0.61–0.82), respectively. Using the optimal cut-off of 27 pg/mL, the sensitivity, specificity, positive predictive value, and negative predictive value of LG2m for diagnosing advanced fibrosis were 60.5%, 86.0%, 48.9%, and 90.7%, respectively. Using the optimal cut-off of 0.75, the corresponding values for the GLAS score were 65.8%, 73.7%, 35.7%, and 90.6%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Serum LG2m level and the GLAS score have fair accuracy for the diagnosis of advanced fibrosis in patients with MASLD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 8","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yield of Synchronous Adenomas and Serrated Polyps in Patients With Positive Stool Tests (mt-sDNA or FIT): Data From the New Hampshire Colonoscopy Registry","authors":"Joseph C. Anderson,&nbsp;William M. Hisey,&nbsp;Christina M. Robinson,&nbsp;Paul J. Limburg,&nbsp;Bonny L. Kneedler,&nbsp;Lynn F. Butterly","doi":"10.1002/jgh3.70444","DOIUrl":"https://doi.org/10.1002/jgh3.70444","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Patients with synchronous conventional adenomas and serrated polyps are at increased risk for metachronous neoplasia. We used New Hampshire Colonoscopy Registry data to examine the prevalence, pathway, and severity of synchronous lesions detected on colonoscopy after positive multi-target-stool DNA (mt-sDNA) or Fecal Immunochemical Tests (FIT), compared to colonoscopies without prior stool test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We estimated the risk of synchronous conventional adenomas and serrated polyps relative to no lesions, adenomas only, and serrated polyps only, across the three study cohorts using multinomial logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We included 1089 mt-sDNA+ patients, 436 FIT+ patients, and 43 379 patients with screening colonoscopy only without previous stool test. Patients with mt-sDNA+ tests had a higher risk of synchronous lesions compared to FIT+ patients (OR = 2.34; 95% CI: 1.70–3.28) and colonoscopy-only patients (OR = 2.92; 95% CI: 2.50–3.40). Mt-sDNA+ patients also had significantly higher risks of serrated polyps versus no polyps (RRR = 2.92; 95% CI: 2.39–3.58) and synchronous polyps versus adenomas alone (RRR = 2.00; 95% CI: 1.67–2.4) compared to colonoscopy-only patients; no such differences were found in the FIT+/colonoscopy-only comparison. Most mt-sDNA+ and FIT+ patients with synchronous lesions had at least one advanced lesion, while the majority of colonoscopy-only patients with synchronous lesions had no advanced lesion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The yield of synchronous conventional adenomas and serrated polyps is higher in patients with positive mt-sDNA tests compared to FIT+ or colonoscopy-only patients, likely due in part to the higher yield of serrated polyps in mt-sDNA+ patients, which persists even among patients with adenomas.</p>\u0000 </section>\u0000 </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 8","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148617397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Helicobacter pylori Infection in Children From Households With Members' History of Successful H. pylori Eradication","authors":"Trang Dinh Linh,&nbsp;Van Hoang Thi Hai,&nbsp;Thuong Nguyen Thu,&nbsp;Uyen Vu Thi Thu,&nbsp;Trang Tran Thi Thu,&nbsp;Anh Le Quynh,&nbsp;Long Hoang Bao,&nbsp;Long Dao Van,&nbsp;Hang Dao Viet","doi":"10.1002/jgh3.70453","DOIUrl":"https://doi.org/10.1002/jgh3.70453","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study investigated the prevalence of <i>Helicobacter pylori</i> infection and associated factors in children from households with members' history of successful <i>H. pylori</i> eradication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional study was conducted from February to December 2024 in Hanoi, Vietnam. Eligible households were those having lived together for at least 12 months, including at least one child under 16 years old and at least one member with successful <i>H. pylori</i> eradication. <i>H. pylori</i> infection status among family members was assessed using stool antigen testing. Data on household demographic characteristics, childcare practices, and infection status of family members were collected. Multivariable logistic regression was used to identify factors associated with infection in children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 193 households with 877 members were included, including 338 children under 16 years old. The prevalence of <i>H. pylori</i> infection was 59% overall and 53% among children. Children living with both infected parents had a higher infection prevalence than those with only one infected parent (58% vs. 38.2%, <i>p</i> &lt; 0.001), with a similar trend observed among infected siblings. After adjustment, parental infection status remained the strongest predictor of infection (aOR = 3.18; 95% CI: 1.83–5.52), while larger household size was inversely associated (aOR = 0.74; 95% CI: 0.58–0.93).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Children's infection risk increased according to the infection status of parents and siblings, while a higher number of family members was associated with a lower likelihood of infection, although this finding should be interpreted with caution, supporting the importance of household-level transmission and family-based prevention strategies in high-prevalence settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 8","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70453","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Tolerability of Tegoprazan Compared to Proton Pump Inhibitors in the Treatment of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Youssef Diab,&nbsp;Charbel Maalouf,&nbsp;Anthony Junior Al Hakim,&nbsp;Perla Chami,&nbsp;Ali Ghais,&nbsp;Etwal Bou Raad,&nbsp;Louis Chaptini","doi":"10.1002/jgh3.70450","DOIUrl":"10.1002/jgh3.70450","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Tegoprazan, a potassium-competitive acid blocker, is an acid-suppressing medication under review as a potential alternative treatment in cases of erosive esophagitis. This systematic review and meta-analysis assesses the efficacy and tolerability of tegoprazan compared to proton pump inhibitors, the current standard of care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Pubmed, Cochrane Library, Web of Science, Scopus, Embase, and Medline Ovid were systematically searched for articles up to November 25, 2025. Inclusion criteria selected RCTs that included patients with erosive esophagitis and studies of safety and efficacy, while exclusion criteria were defined by nonhuman studies, healthy patient populations, <i>Helicobacter pylori</i>-positive populations, and non-RCT publication types. This review was registered with PROSPERO (CRD42024602209).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of 724 screened studies, 5 RCTs were selected for this review, with a total of 1386 patients. Tegoprazan efficacy outcomes were consistent with non-inferiority when compared to PPIs in the healing of erosive esophagitis (risk ratio: 1.03, 95% confidence interval: 1.00–1.07), as confirmed endoscopically. Comparable tolerability was also demonstrated (rate ratio: 0.97, 95% confidence interval: 0.68–1.37), with a similar distribution of treatment-emergent adverse events across treatment groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Tegoprazan was non-inferior to PPIs in both efficacy and tolerability, in accordance with the definition of non-inferiority set by the RCTs. This supports its potential use as an alternative treatment in patients with erosive esophagitis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 8","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13408013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148608465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioimpedance Analysis to Predict Clinical Outcomes of Liver Cirrhosis in a Prospective Cohort Study","authors":"Mohammed Kanan,&nbsp;Michelle Luster,&nbsp;Saira Khaderi,&nbsp;Fasiha Kanwal,&nbsp;Aaron P. Thrift,&nbsp;Abeer Alsarraj,&nbsp;Emad Sorial,&nbsp;Emad Salem,&nbsp;Hao Duong,&nbsp;Hashem B. El-Serag","doi":"10.1002/jgh3.70441","DOIUrl":"10.1002/jgh3.70441","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Bioimpedance analysis (BIA) is a non-invasive method for estimating body composition, which plays a role in the development of cirrhosis. We investigated if BIA measures were associated with cirrhosis complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed data from 566 participants in a prospective cohort study of cirrhosis patients from tertiary care clinics who underwent BIA at enrollment and regular follow up (20.3% female; 47.0% non-Hispanic White, 23.1% Hispanic, 27.7% Black; 47.7% metabolic and alcohol-associated liver disease [MetALD], 30.4% metabolic dysfunction-associated steatotic liver disease [MASLD], 1.9% alcohol-associated liver disease [ALD], 9.0% active hepatitis C virus [HCV]). We performed multivariable logistic regression to assess the association of BIA measures with etiology and prevalent decompensation and Cox proportional hazards regression to assess incident decompensation and HCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After adjustment for sex and race, body fat mass was associated with 14-fold increased odds of MASLD (adjusted odds ratio [aOR] 14.10, 95% confidence interval [CI] 5.25–37.85) and decreased odds of ALD (aOR 0.73, 95% CI 0.60–0.88). Lower odds of prevalent decompensation were seen in the highest tertile of trunk lean mass (aOR 0.39, 95% CI 0.21–0.73) and left arm lean mass (aOR 0.40, 95% CI 0.21–0.75) compared with their lowest tertiles. The middle tertile of visceral fat surface area showed an inverse association with incident decompensation (adjusted hazard ratio 0.19, 95% CI 0.04–0.88). There were no significant associations between BIA measures and incident HCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>BIA could be used as a prognostic tool for patients with cirrhosis, supporting its incorporation into clinical workflows.</p>\u0000 </section>\u0000 </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 8","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148608462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Concerning the Article: Impact of Quinolone Prophylaxis on Spontaneous Bacterial Peritonitis and Mortality in Cirrhosis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Alejandro Chen Liang,&nbsp;Yeison Cruz Castillo,&nbsp;Lorena M. Murrieta,&nbsp;Jesus Eleazar Angulo Durazo,&nbsp;Hector Jonan Flores Uribe","doi":"10.1002/jgh3.70451","DOIUrl":"10.1002/jgh3.70451","url":null,"abstract":"<p>We read with great interest the recent meta-analysis evaluating quinolone prophylaxis for the prevention of spontaneous bacterial peritonitis (SBP) and mortality in patients with cirrhosis by Malvi et al. [<span>1</span>]. We commend the authors for addressing a clinically important question and for conducting a systematic review and meta-analysis of randomized controlled trials in this field.</p><p>First, regarding the assessment of risk of bias, the authors reported the use of the Cochrane Risk of Bias 2.0 (RoB 2) tool. However, based on the domain-level assessments presented, several studies classified as overall “low risk” include at least one domain rated as “some concerns,” particularly in relation to missing outcome data. According to RoB 2 guidance, an overall “low risk” judgment requires all domains to be rated as low risk; the presence of any domain with “some concerns” would preclude this classification. Clarification on how overall judgments were derived would help contextualize these study-level assessments [<span>2-4</span>].</p><p>Second, while the review focuses on randomized controlled trials, clarification regarding the eligibility criteria for comparator groups would be valuable. Although quinolone prophylaxis is defined as the intervention of interest, the comparator is not explicitly specified. As included studies are predominantly presented as placebo-controlled, it would be helpful to clarify whether trials with active comparators were considered during study selection, as this may influence the scope and interpretability of the pooled estimates.</p><p>Additionally, recurring considerations within the same risk-of-bias domain across multiple studies may have implications for the overall certainty of the evidence and its interpretation.</p><p>Overall, further clarity in methodological reporting, particularly regarding risk of bias assessment and study selection decisions, may help strengthen the transparency and interpretability of the findings. In line with PRISMA 2020 Statement recommendations, transparent reporting of these processes is essential to ensure reproducibility and allow readers to fully assess the validity of the findings [<span>2</span>].</p><p>The authors declare no conflicts of interest.</p><p>Data sharing not applicable to this article as no datasets were generated or analysed during the current study.</p>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 7","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148594004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Colorectal Cancer in Africa: A Multicenter Study on Epidemiology, Management, and Outcomes Between 2000 and 2023","authors":"Jaques van Heerden,&nbsp;Joyce Balagadde-Kambugu,&nbsp;Veronica Nyakato,&nbsp;Pamela Mwa,&nbsp;Fadhil Geriga,&nbsp;Barnabas Atwiine,&nbsp;Victoria Mwebe Katasi,&nbsp;Sarra Benmiloud,&nbsp;Laila Hessissen,&nbsp;Imène Chabchoub,&nbsp;Leolin Katsidzira,&nbsp;Eno-Obong Bassey,&nbsp;Gashaw Arega,&nbsp;Ané Büchner,&nbsp;Jan du Plessis,&nbsp;Mark Siboe,&nbsp;Edrick Elias,&nbsp;Mulingilu Isabel Lumeka,&nbsp;Francine Kouya,&nbsp;Vivian Paintsil,&nbsp;Michelle Obat,&nbsp;Sarah Muma,&nbsp;Olufemi Adefehinti,&nbsp;Adeseye Michael Akinsete,&nbsp;Oluwafunmilayo Toyin Fagbemide,&nbsp;Ndeye Khady Ngom,&nbsp;Sara Marouf,&nbsp;Khaled Seddik,&nbsp;Salah Ahmed,&nbsp;Amany Mohamed Ali,&nbsp;Esraa Abdelkeriem,&nbsp;Reem Ragab,&nbsp;Yomna Mohamed,&nbsp;Moatasem Elayadi,&nbsp;SIOP Africa Scientific Committee","doi":"10.1002/jgh3.70445","DOIUrl":"10.1002/jgh3.70445","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Colorectal cancer (CRC) is increasing in Africa, yet reports in children and adolescents are limited. We describe the epidemiology, management, and survival outcomes of CRC in African children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective data of children under 19 years diagnosed with CRC between 2000 and 2023 were collected from 14 African countries. Patient and tumor characteristics and treatment data were described and survival outcomes analyzed. GLOBOCAN data were used to evaluate age-related geographical distribution of CRC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Hundred-and-eight patients, 57.4% males, were diagnosed with a mean age of 14.9 (range 5–18) years. The mean symptom-onset-to-diagnosis duration was 90 days (range 2–1200). Most common symptoms were abdominal discomfort (70.6%) and change in bowel habits (57.8%). The commonest primary site was the ascending colon (30.6%) with a mean tumor size of 64.3 mm (range 30–150 mm) and 37% presenting in stage III and 36.1% in stage IV. Most (83.3%) tumors were confirmed on histology, of which 78.7% were adenocarcinoma. Carcinoembryonic antigen was performed in 38.9% of patients. Complete resection was achieved in 55.6% of cases, while 18.5% received radiotherapy. Folinic acid, Fluorouracil, Oxaliplatin (FOLFOX) was the first line chemotherapy in 48.1% of patients. A third of patients were lost to follow-up while 25.6% experienced disease progression. The 2-year and 5-year overall survival rates were 40.0% and 16.9%, respectively. Disease stage (<i>p</i> = 0.07) and degree of resection (<i>p</i> = 0.02) predicted outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pediatric CRC is characterized by delayed diagnosis and advanced stage presentation, contributing to a significantly lower overall survival compared to adults. Focused research and multidisciplinary management are needed to understand pediatric CRC and improve outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"10 7","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13395961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148585482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}